Entrada Therapeutics Statistics
Total Valuation
TRDA has a market cap or net worth of $259.89 million. The enterprise value is -$39.38 million.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TRDA has 35.55 million shares outstanding. The number of shares has increased by 19.72% in one year.
| Current Share Class | 35.55M |
| Shares Outstanding | 35.55M |
| Shares Change (YoY) | +19.72% |
| Shares Change (QoQ) | +0.65% |
| Owned by Insiders (%) | 1.12% |
| Owned by Institutions (%) | 50.39% |
| Float | 19.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.77 |
| Forward PS | 6.18 |
| PB Ratio | 0.68 |
| P/TBV Ratio | 0.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.64, with a Debt / Equity ratio of 0.14.
| Current Ratio | 18.64 |
| Quick Ratio | 18.05 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -18.12% and return on invested capital (ROIC) is -12.94%.
| Return on Equity (ROE) | -18.12% |
| Return on Assets (ROA) | -11.66% |
| Return on Invested Capital (ROIC) | -12.94% |
| Return on Capital Employed (ROCE) | -22.42% |
| Revenue Per Employee | $434,295 |
| Profits Per Employee | -$400,836 |
| Employee Count | 183 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.55M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.97% in the last 52 weeks. The beta is -0.11, so TRDA's price volatility has been lower than the market average.
| Beta (5Y) | -0.11 |
| 52-Week Price Change | -56.97% |
| 50-Day Moving Average | 5.74 |
| 200-Day Moving Average | 8.26 |
| Relative Strength Index (RSI) | 69.93 |
| Average Volume (20 Days) | 182,963 |
Short Selling Information
The latest short interest is 944,223, so 2.66% of the outstanding shares have been sold short.
| Short Interest | 944,223 |
| Short Previous Month | 813,393 |
| Short % of Shares Out | 2.66% |
| Short % of Float | 4.95% |
| Short Ratio (days to cover) | 2.86 |
Income Statement
In the last 12 months, TRDA had revenue of $79.48 million and -$73.35 million in losses. Loss per share was -$1.79.
| Revenue | 79.48M |
| Gross Profit | -55.14M |
| Operating Income | -96.16M |
| Pretax Income | -76.91M |
| Net Income | -73.35M |
| EBITDA | -92.26M |
| EBIT | -96.16M |
| Loss Per Share | -$1.79 |
Full Income StatementBalance Sheet
The company has $354.01 million in cash and $54.74 million in debt, giving a net cash position of $299.27 million or $8.42 per share.
| Cash & Cash Equivalents | 354.01M |
| Total Debt | 54.74M |
| Net Cash | 299.27M |
| Net Cash Per Share | $8.42 |
| Equity (Book Value) | 379.51M |
| Book Value Per Share | 10.68 |
| Working Capital | 349.34M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$123.87 million and capital expenditures -$2.69 million, giving a free cash flow of -$126.56 million.
| Operating Cash Flow | -123.87M |
| Capital Expenditures | -2.69M |
| Free Cash Flow | -126.56M |
| FCF Per Share | -$3.56 |
Full Cash Flow StatementMargins
Gross margin is -69.38%, with operating and profit margins of -121.00% and -92.30%.
| Gross Margin | -69.38% |
| Operating Margin | -121.00% |
| Pretax Margin | -96.77% |
| Profit Margin | -92.30% |
| EBITDA Margin | -116.08% |
| EBIT Margin | -121.00% |
| FCF Margin | n/a |
Dividends & Yields
TRDA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.72% |
| Shareholder Yield | -19.72% |
| Earnings Yield | -28.22% |
| FCF Yield | -48.70% |
Analyst Forecast
The average price target for TRDA is $25.67, which is 251.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.67 |
| Price Target Difference | 251.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TRDA has an Altman Z-Score of 3.99 and a Piotroski F-Score of 1.
| Altman Z-Score | 3.99 |
| Piotroski F-Score | 1 |
